Clinical potential and challenges of using genetically modified cells for articular cartilage repair

Croatian Medical Journal

Volumn 52, Issue 3, 2011, Pages 245-261

  Madry, Henning ^a   Cucchiarini, Magali ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RECOMBINANT SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ADIPOSE TISSUE; APOPTOSIS; ARTICLE; ARTICULAR CARTILAGE; ARTICULAR CARTILAGE DEFECT; CARTILAGE; CARTILAGE CELL; CARTILAGE INJURY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL REGENERATION; CELL THERAPY; CHONDROCYTE IMPLANTATION; CHONDROGENESIS; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSFER; GENE VECTOR; GENETIC ENGINEERING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOARTHRITIS; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARTILAGE, ARTICULAR; CHONDROCYTES; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; NIH 3T3 CELLS;

EID: 80051921186     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2011.52.245     Document Type: Article

References (145)

1. Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, et al. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther. 1996;7:1261-80.
2. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A. 2005;102:8698-703.
3. Evans CH, Ghivizzani SC, Robbins PD. Getting arthritis gene therapy into the clinic. Nat Rev Rheumatol. 2011;7:244-9.
4. Madry H, van Dijk CN, Mueller-Gerbl M. The basic science of the subchondral bone. Knee Surg Sports Traumatol Arthrosc. 2010;18:419-33.
5. Jackson DW, Simon TM, Aberman HM. Symptomatic articular cartilage degeneration: the impact in the new millennium. Clin Orthop Relat Res. 2001;(Suppl):S14-25.
6. Gomoll AH, Farr J, Gillogly SD, Kercher JS, Minas T. Surgical management of articular cartilage defects of the knee. Instr Course Lect. 2011;60:461-83.
7. Cucchiarini M, Madry H. Gene therapy for cartilage defects. J Gene Med. 2005;7:1495-509.
8. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, et al. Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo. Arthritis Rheum. 1996;39:820-8.
9. Kaul G, Cucchiarini M, Arntzen D, Zurakowski D, Menger MD, Kohn D, et al. Local stimulation of articular cartilage repair by transplantation of encapsulated chondrocytes overexpressing human fibroblast growth factor 2 (FGF-2) in vivo. J Gene Med. 2006;8:100-11.
10. Madry H, Kaul G, Cucchiarini M, Stein U, Zurakowski D, Remberger K, et al. Enhanced repair of articular cartilage defects in vivo by transplanted chondrocytes overexpressing insulin-like growth factor I (IGF-I). Gene Ther. 2005;12:1171-9.
11. Gerich TG, Lobenhoffer HP, Fu FH, Robbins PD, Evans CH. Virally mediated gene transfer in the patellar tendon. An experimental study in rabbits [in German]. Unfallchirurg. 1997;100:354-62.
12. Madry H, Emkey G, Zurakowski D, Trippel SB. Overexpression of human fibroblast growth factor 2 stimulates cell proliferation in an ex vivo model of articular chondrocyte transplantation. J Gene Med. 2004;6:238-45.
13. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res. 2002;20:169-73.
14. Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9:372-80.
15. Tsuchiya H, Kitoh H, Sugiura F, Ishiguro N. Chondrogenesis enhanced by overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun. 2003;301:338-43.
16. Grossin L, Cournil-Henrionnet C, Pinzano A, Gaborit N, Dumas D, Etienne S, et al. Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. FASEB J. 2006;20:65-75.
17. Yeh LC, Lee JC. Co-transfection with the osteogenic protein (OP)-1 gene and the insulin-like growth factor (IGF)-I gene enhanced osteoblastic cell differentiation. Biochim Biophys Acta. 2006;1763:57-63.
18. Zhang HN, Leng P, Wang YZ, Zhang J. Treating human meniscal fibrochondrocytes with hIGF-1 gene by liposome. Clin Orthop Relat Res. 2009;467:3175-82.
19. Manning K, Rachakonda PS, Rai MF, Schmidt MF. Coexpression of insulin-like growth factor-1 and interleukin-4 in an in vitro inflammatory model. Cytokine. 2010;50:297-305.
20. Madry H, Zurakowski D, Trippel SB. Overexpression of human insulin-like growth factor-I promotes new tissue formation in an ex vivo model of articular chondrocyte transplantation. Gene Ther. 2001;8:1443-9.
21. Li Y, Tew SR, Russell AM, Gonzalez KR, Hardingham TE, Hawkins RE. Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. Tissue Eng. 2004;10:575-84.
22. Attur MG, Dave MN, Leung MY, Cipolletta C, Meseck M, Woo SL, et al. Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol. 2002;168:2001-10.
23. Smith P, Shuler FD, Georgescu HI, Ghivizzani SC, Johnstone B, Niyibizi C, et al. Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-1. Arthritis Rheum. 2000;43:1156-64.
24. Goto H, Shuler FD, Lamsam C, Moller HD, Niyibizi C, Fu FH, et al. Transfer of lacZ marker gene to the meniscus. J Bone Joint Surg Am. 1999;81:918-25.
25. Gerich TG, Kang R, Fu FH, Robbins PD, Evans CH. Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. Gene Ther. 1996;3:1089-93.
26. Lou J, Kubota H, Hotokezaka S, Ludwig FJ, Manske PR. In vivo gene transfer and overexpression of focal adhesion kinase (pp125 FAK) mediated by recombinant adenovirus-induced tendon adhesion formation and epitenon cell change. J Orthop Res. 1997;15:911-8.
27. Mehrara BJ, Saadeh PB, Steinbrech DS, Dudziak M, Spector JA, Greenwald JA, et al. Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo. J Bone Miner Res. 1999;14:1290-301.
28. Nixon AJ, Brower-Toland BD, Bent SJ, Saxer RA, Wilke MJ, Robbins PD, et al. Insulinlike growth factor-I gene therapy applications for cartilage repair. Clin Orthop Relat Res. 2000;(Suppl):S201-13.
29. Shuler FD, Georgescu HI, Niyibizi C, Studer RK, Mi Z, Johnstone B, et al. Increased matrix synthesis following adenoviral transfer of a transforming growth factor beta1 gene into articular chondrocytes. J Orthop Res. 2000;18:585-92.
30. B rower-Toland BD, Saxer RA, Goodrich LR, Mi Z, Robbins PD, Evans CH, et al. Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. Hum Gene Ther. 2001;12:117-29.
31. Gelse K, Jiang QJ, Aigner T, Ritter T, Wagner K, Poschl E, et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum. 2001;44:1943-53.
32. Saxer RA, Bent SJ, Brower-Toland BD, Mi Z, Robbins PD, Evans CH, et al. Gene mediated insulin-like growth factor-I delivery to the synovium. J Orthop Res. 2001;19:759-67.
33. Musgrave DS, Pruchnic R, Bosch P, Ziran BH, Whalen J, Huard J. Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. J Bone Joint Surg Br. 2002;84:120-7.
34. Ikeda T, Kamekura S, Mabuchi A, Kou I, Seki S, Takato T, et al. The combination of SOX5, SOX6, and SOX9 (the SOX trio) provides signals sufficient for induction of permanent cartilage. Arthritis Rheum. 2004;50:3561-73.
35. Haupt JL, Frisbie DD, McIlwraith CW, Robbins PD, Ghivizzani S, Evans CH, et al. Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res. 2005;23:118-26.
36. Nixon AJ, Haupt JL, Frisbie DD, Morisset SS, McIlwraith CW, Robbins PD, et al. Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy. Gene Ther. 2005;12:177-86.
37. Steinert AF, Palmer GD, Capito R, Hofstaetter JG, Pilapil C, Ghivizzani SC, et al. Genetically enhanced engineering of meniscus tissue using ex vivo delivery of transforming growth factor-beta 1 complementary deoxyribonucleic acid. Tissue Eng. 2007;13:2227-37.
38. Steinert AF, Proffen B, Kunz M, Hendrich C, Ghivizzani SC, Noth U, et al. Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. Arthritis Res Ther. 2009;11:R148.
39. Mason JM, Breitbart AS, Barcia M, Porti D, Pergolizzi RG, Grande DA. Cartilage and bone regeneration using gene-enhanced tissue engineering. Clin Orthop Relat Res. 2000;(Suppl):S171-8.
40. Roessler BJ, Hartman JW, Vallance DK, Latta JM, Janich SL, Davidson BL. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther. 1995;6:307-16.
41. B altzer AW, Whalen JD, Muzzonegro T, Georgescu HI, Robbins PD, Evans CH. In vitro transduction of human osteoblast cell populations with retroviral vectors [in German]. Z Rheumatol. 1999;58:88-94.
42. Hildebrand KA, Deie M, Allen CR, Smith DW, Georgescu HI, Evans CH, et al. Early expression of marker genes in the rabbit medial collateral and anterior cruciate ligaments: the use of different viral vectors and the effects of injury. J Orthop Res. 1999;17:37-42.
43. Goto H, Shuler FD, Niyibizi C, Fu FH, Robbins PD, Evans CH. Gene therapy for meniscal injury: enhanced synthesis of proteoglycan and collagen by meniscal cells transduced with a TGFbeta(1) gene. Osteoarthritis Cartilage. 2000;8:266-71.
44. Tew SR, Li Y, Pothacharoen P, Tweats LM, Hawkins RE, Hardingham TE. Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. Osteoarthritis Cartilage. 2005;13:80-9.
45. Cucchiarini M, Madry H, Ma C, Thurn T, Zurakowski D, Menger MD, et al. Improved tissue repair in articular cartilage defects in vivo by rAAV-mediated overexpression of human fibroblast growth factor 2. Mol Ther. 2005;12:229-38.
46. Pagnotto MR, Wang Z, Karpie JC, Ferretti M, Xiao X, Chu CR. Adeno associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. Gene Ther. 2007;14:804-13.
47. Madry H, Cucchiarini M, Terwilliger EF, Trippel SB. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther. 2003;14:393-402.
48. Yokoo N, Saito T, Uesugi M, Kobayashi N, Xin KQ, Okuda K, et al. Repair of articular cartilage defect by autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector. Arthritis Rheum. 2005;52:164-70.
49. Jennings K, Miyamae T, Traister R, Marinov A, Katakura S, Sowders D, et al. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther. 2005;11:600-7.
50. Goater J, Muller R, Kollias G, Firestein GS, Sanz I, O'Keefe RJ, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol. 2000;27:983-9.
51. Zhang HG, Xie J, Yang P, Wang Y, Xu L, Liu D, et al. Adenoassociated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther. 2000;11:2431-42.
52. Hiraide A, Yokoo N, Xin KQ, Okuda K, Mizukami H, Ozawa K, et al. Repair of articular cartilage defect by intraarticular administration of basic fibroblast growth factor gene, using adeno-associated virus vector. Hum Gene Ther. 2005;16:1413-21.
53. Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther. 2002;13:1179-88.
54. Arai Y, Kubo T, Fushiki S, Mazda O, Nakai H, Iwaki Y, et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J Rheumatol. 2000;27:979-82.
55. Ulrich-Vinther M, Maloney MD, Goater JJ, Soballe K, Goldring MB, O'Keefe RJ, et al. Light-activated gene transduction enhances adeno-associated virus vector-mediated gene expression in human articular chondrocytes. Arthritis Rheum. 2002;46:2095-104.
56. Cucchiarini M, Thurn T, Weimer A, Kohn D, Terwilliger EF, Madry H. Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor SOX9. Arthritis Rheum. 2007;56:158-67.
57. Cucchiarini M, Terwilliger EF, Kohn D, Madry H. Remodelling of human osteoarthritic cartilage by FGF-2, alone or combined with Sox9 via rAAV gene transfer. J Cell Mol Med. 2009;13:2476-88.
58. Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science. 2004;303:1198-201.
59. Ito H, Goater JJ, Tiyapatanaputi P, Rubery PT, O'Keefe RJ, Schwarz EM. Light-activated gene transduction of recombinant adenoassociated virus in human mesenchymal stem cells. Gene Ther. 2004;11:34-41.
60. B asile P, Dadali T, Jacobson J, Hasslund S, Ulrich-Vinther M, Soballe K, et al. Freeze-dried tendon allografts as tissue-engineering scaffolds for Gdf5 gene delivery. Mol Ther. 2008;16:466-73.
61. Arsic N, Zacchigna S, Zentilin L, Ramirez-Correa G, Pattarini L, Salvi A, et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther. 2004;10:844-54.
62. Madry H, Cucchiarini M, Kaul G, Kohn D, Terwilliger EF, Trippel SB. Menisci are efficiently transduced by recombinant adeno-associated virus vectors in vitro and in vivo. Am J Sports Med. 2004;32:1860-5.
63. Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J, et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med. 2005;11:291-7.
64. Wang XT, Liu PY, Xin KQ, Tang JB. Tendon healing in vitro: bFGF gene transfer to tenocytes by adeno-associated viral vectors promotes expression of collagen genes. J Hand Surg Am. 2005;30:1255-61.
65. Tang JB, Cao Y, Zhu B, Xin KQ, Wang XT, Liu PY. Adeno-associated virus-2-mediated bFGF gene transfer to digital flexor tendons significantly increases healing strength. an in vivo study. J Bone Joint Surg Am. 2008;90:1078-89.
66. Cucchiarini M, Schetting S, Terwilliger EF, Kohn D, Madry H. rAAVmediated overexpression of FGF-2 promotes cell proliferation, survival, and alpha-SMA expression in human meniscal lesions. Gene Ther. 2009;16:1363-72.
67. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098-108.
68. Kafienah W, Al-Fayez F, Hollander AP, Barker MD. Inhibition of cartilage degradation: a combined tissue engineering and gene therapy approach. Arthritis Rheum. 2003;48:709-18.
69. Bondeson J, Lauder S, Wainwright S, Amos N, Evans A, Hughes C, et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol. 2007;34:523-33.
70. Baragi VM, Renkiewicz RR, Jordan H, Bonadio J, Hartman JW, Roessler BJ. Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. J Clin Invest. 1995;96:2454-60.
71. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol. 2001;166:3499-505.
72. Schmal H, Mehlhorn AT, Zwingmann J, Muller CA, Stark GB, Sudkamp NP. Stimulation of chondrocytes in vitro by gene transfer with plasmids coding for epidermal growth factor (hEGF) and basic fibroblast growth factor (bFGF). Cytotherapy. 2005;7:292-300.
73. Lee DK, Choi KB, Oh IS, Song SU, Hwang S, Lim CL, et al. Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. Tissue Eng. 2005;11:310-8.
74. Surendran S, Kim SH, Jee BK, Ahn SH, Gopinathan P, Han CW. Antiapoptotic Bcl-2 gene transfection of human articular chondrocytes protects against nitric oxide-induced apoptosis. J Bone Joint Surg Br. 2006;88:1660-5.
75. Piera-Velazquez S, Jimenez SA, Stokes D. Increased life span of human osteoarthritic chondrocytes by exogenous expression of telomerase. Arthritis Rheum. 2002;46:683-93.
76. Madry H, Orth P, Kaul G, Zurakowski D, Menger MD, Kohn D, et al. Acceleration of articular cartilage repair by combined gene transfer of human insulin-like growth factor I and fibroblast growth factor-2 in vivo. Arch Orthop Trauma Surg. 2010;130:1311-22.
77. Dharmavaram RM, Liu G, Tuan RS, Stokes DG, Jimenez SA. Stable transfection of human fetal chondrocytes with a type II procollagen minigene: expression of the mutant protein and alterations in the structure of the extracellular matrix in vitro. Arthritis Rheum. 1999;42:1433-42.
78. Venkatesan N, Barre L, Benani A, Netter P, Magdalou J, Fournel-Gigleux S, et al. Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair. Proc Natl Acad Sci U S A. 2004;101:18087-92.
79. Doherty PJ, Zhang H, Tremblay L, Manolopoulos V, Marshall KW. Resurfacing of articular cartilage explants with geneticallymodified human chondrocytes in vitro. Osteoarthritis Cartilage. 1998;6:153-9.
80. Hidaka C, Quitoriano M, Warren RF, Crystal RG. Enhanced matrix synthesis and in vitro formation of cartilage-like tissue by genetically modified chondrocytes expressing BMP-7. J Orthop Res. 2001;19:751-8.
81. Madry H, Trippel SB. Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Ther. 2000;7:286-91.
82. Pascher A, Palmer GD, Steinert A, Oligino T, Gouze E, Gouze JN, et al. Gene delivery to cartilage defects using coagulated bone marrow aspirate. Gene Ther. 2004;11:133-41.
83. Fragonas E, Valente M, Pozzi-Mucelli M, Toffanin R, Rizzo R, Silvestri F, et al. Articular cartilage repair in rabbits by using suspensions of allogenic chondrocytes in alginate. Biomaterials. 2000;21:795-801.
84. Rahfoth B, Weisser J, Sternkopf F, Aigner T, von der Mark K, Brauer R. Transplantation of allograft chondrocytes embedded in agarose gel into cartilage defects of rabbits. Osteoarthritis Cartilage. 1998;6:50-65.
85. Hunter CJ, Levenston ME. Maturation and integration of tissue-engineered cartilages within an in vitro defect repair model. Tissue Eng. 2004;10:736-46.
86. Kawamura S, Wakitani S, Kimura T, Maeda A, Caplan AI, Shino K, et al. Articular cartilage repair. Rabbit experiments with a collagen gel-biomatrix and chondrocytes cultured in it. Acta Orthop Scand. 1998;69:56-62.
87. Ikeda T, Kubo T, Nakanishi T, Arai Y, Kobayashi K, Mazda O, et al. Ex vivo gene delivery using an adenovirus vector in treatment for cartilage defects. J Rheumatol. 2000;27:990-6.
88. Perka C, Schultz O, Spitzer RS, Lindenhayn K. The influence of transforming growth factor beta1 on mesenchymal cell repair of full-thickness cartilage defects. J Biomed Mater Res. 2000;52:543-52.
89. Driesang IM, Hunziker EB. Delamination rates of tissue flaps used in articular cartilage repair. J Orthop Res. 2000;18:909-11.
90. Freed LE, Grande DA, Lingbin Z, Emmanual J, Marquis JC, Langer R. Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds. J Biomed Mater Res. 1994;28:891-9.
91. Perka C, Sittinger M, Schultz O, Spitzer RS, Schlenzka D, Burmester GR. Tissue engineered cartilage repair using cryopreserved and noncryopreserved chondrocytes. Clin Orthop Relat Res. 2000;(378):245-54.
92. Schaefer D, Martin I, Jundt G, Seidel J, Heberer M, Grodzinsky A, et al. Tissue-engineered composites for the repair of large osteochondral defects. Arthritis Rheum. 2002;46:2524-34.
93. Kang R, Marui T, Ghivizzani SC, Nita IM, Georgescu HI, Suh JK, et al. Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage. 1997;5:139-43.
94. Madry H, Cucchiarini M, Stein U, Remberger K, Menger MD, Kohn D, et al. Sustained transgene expression in cartilage defects in vivo after transplantation of articular chondrocytes modified by lipidmediated gene transfer in a gel suspension delivery system. J Gene Med. 2003;5:502-9.
95. Goomer RS, Deftos LJ, Terkeltaub R, Maris T, Lee MC, Harwood FL, et al. High-efficiency non-viral transfection of primary chondrocytes and perichondrial cells for ex-vivo gene therapy to repair articular cartilage defects. Osteoarthritis Cartilage. 2001;9:248-56.
96. Ueblacker P, Wagner B, Kruger A, Vogt S, DeSantis G, Kennerknecht E, et al. Inducible nonviral gene expression in the treatment of osteochondral defects. Osteoarthritis Cartilage. 2004;12:711-9.
97. Mason JM, Grande DA, Barcia M, Grant R, Pergolizzi RG, Breitbart AS. Expression of human bone morphogenic protein in primary rabbit periosteal cells: potential utility in gene therapy for osteochondral repair. Gene Ther. 1998;5:1098-104.
98. Adachi N, Sato K, Usas A, Fu FH, Ochi M, Han CW, et al. Muscle derived, cell based ex vivo gene therapy for treatment of full thickness articular cartilage defects. J Rheumatol. 2002;29:1920-30.
99. Hirschmann F, Verhoeyen E, Wirth D, Bauwens S, Hauser H, Rudert M. Vital marking of articular chondrocytes by retroviral infection using green fluorescence protein. Osteoarthritis Cartilage. 2002;10:109-18.
100. Mierisch CM, Wilson HA, Turner MA, Milbrandt TA, Berthoux L, Hammarskjold ML, et al. Chondrocyte transplantation into articular cartilage defects with use of calcium alginate: the fate of the cells. J Bone Joint Surg Am. 2003;85-A:1757-67.
101. Kobayashi N, Koshino T, Uesugi M, Yokoo N, Xin KQ, Okuda K, et al. Gene marking in adeno-associated virus vector infected periosteum derived cells for cartilage repair. J Rheumatol. 2002;29:2176-80.
102. Hidaka C, Goodrich LR, Chen CT, Warren RF, Crystal RG, Nixon AJ. Acceleration of cartilage repair by genetically modified chondrocytes over expressing bone morphogenetic protein-7. J Orthop Res. 2003;21:573-83.
103. B aragi VM, Renkiewicz RR, Qiu L, Brammer D, Riley JM, Sigler RE, et al. Transplantation of adenovirally transduced allogeneic chondrocytes into articular cartilage defects in vivo. Osteoarthritis Cartilage. 1997;5:275-82.
104. Lee KH, Song SU, Hwang TS, Yi Y, Oh IS, Lee JY, et al. Regeneration of hyaline cartilage by cell-mediated gene therapy using transforming growth factor beta 1-producing fibroblasts. Hum Gene Ther. 2001;12:1805-13.
105. Romagnolo D, Akers RM, Wong EA, Boyle PL, McFadden TB, Turner JD. Overexpression of ovine insulin-like growth factor-I stimulates autonomous autocrine or paracrine growth in bovine mammary-derived epithelial cells. Mol Endocrinol. 1992;6:1774-80.
106. Eming SA, Snow RG, Yarmush ML, Morgan JR. Targeted expression of insulin-like growth factor to human keratinocytes: modification of the autocrine control of keratinocyte proliferation. J Invest Dermatol. 1996;107:113-20.
107. Patel RS, Temu TM, Jeanbart L, Morgan JR, Lysaght MJ. A localizable, biological-based system for the delivery of bioactive IGF-1 utilizing microencapsulated genetically modified human fibroblasts. ASAIO J. 2009;55:259-65.
108. Park J, Gelse K, Frank S, von der Mark K, Aigner T, Schneider H. Transgene-activated mesenchymal cells for articular cartilage repair: a comparison of primary bone marrow-, perichondrium/ periosteum- and fat-derived cells. J Gene Med. 2006;8:112-25.
109. Turgeman G, Pittman DD, Muller R, Kurkalli BG, Zhou S, Pelled G, et al. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J Gene Med. 2001;3:240-51.
110. Che JH, Zhang ZR, Li GZ, Tan WH, Bai XD, Qu FJ. Application of tissue-engineered cartilage with BMP-7 gene to repair knee joint cartilage injury in rabbits. Knee Surg Sports Traumatol Arthrosc. 2010;18:496-503.
111. Gelse K, Muhle C, Franke O, Park J, Jehle M, Durst K, et al. Cellbased resurfacing of large cartilage defects: long-term evaluation of grafts from autologous transgene-activated periosteal cells in a porcine model of osteoarthritis. Arthritis Rheum. 2008;58:475-88.
112. Gysin R, Wergedal JE, Sheng MH, Kasukawa Y, Miyakoshi N, Chen ST, et al. Ex vivo gene therapy with stromal cells transduced with a retroviral vector containing the BMP4 gene completely heals critical size calvarial defect in rats. Gene Ther. 2002;9:991-9.
113. Vogt S, Wexel G, Tischer T, Schillinger U, Ueblacker P, Wagner B, et al. The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. Biomaterials. 2009;30:2385-92.
114. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. J Bone Joint Surg Br. 2007;89:672-85.
115. Kuroda R, Usas A, Kubo S, Corsi K, Peng H, Rose T, et al. Cartilage repair using bone morphogenetic protein 4 and muscle-derived stem cells. Arthritis Rheum. 2006;54:433-42.
116. Guo X, Zheng Q, Yang S, Shao Z, Yuan Q, Pan Z, et al. Repair of full-thickness articular cartilage defects by cultured mesenchymal stem cells transfected with the transforming growth factor beta1 gene. Biomed Mater. 2006;1:206-15.
117. Katayama R, Wakitani S, Tsumaki N, Morita Y, Matsushita I, Gejo R, et al. Repair of articular cartilage defects in rabbits using CDMP1 gene-transfected autologous mesenchymal cells derived from bone marrow. Rheumatology (Oxford). 2004;43:980-5.
118. Ivkovic A, Pascher A, Hudetz D, Maticic D, Jelic M, Dickinson S, et al. Articular cartilage repair by genetically modified bone marrow aspirate in sheep. Gene Ther. 2010;17:779-89.
119. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A. 1993;90:10764-8.
120. Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther. 1994;1:64-9.
121. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS Jr, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A. 1996;93:402-6.
122. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol. 1996;156:3558-62.
123. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997;40:1012-9.
124. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res. 2004;22:742-50.
125. Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther. 2002;6:591-600.
126. Matsumoto T, Cooper GM, Gharaibeh B, Meszaros LB, Li G, Usas A, et al. Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. Arthritis Rheum. 2009;60:1390-405.
127. Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop Relat Res. 2000;(Suppl):S300-7.
128. Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther. 2004;11:379-89.
129. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next? Arthritis Rheum. 2006;54:1714-29.
130. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy's first death. Arthritis Res Ther. 2008;10:110.
131. Evans CH, Ghivizzani SC, Oligino TJ, Robbins PD. Gene therapy for autoimmune disorders. J Clin Immunol. 2000;20:334-46.
132. Evans CH. Gene therapy: what have we accomplished and where do we go from here? J Rheumatol Suppl. 2005;72:17-20.
133. Wehling P, Reinecke J, Baltzer AW, Granrath M, Schulitz KP, Schultz C, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009;20:97-101.
134. Evans CH, Ghivizzani SC, Robbins PD. The 2003 Nicolas Andry Award. Orthopaedic gene therapy. Clin Orthop Relat Res. 2004;(429):316-29.
135. Evans CH, Ghivizzani SC, Herndon JH, Robbins PD. Gene therapy for the treatment of musculoskeletal diseases. J Am Acad Orthop Surg. 2005;13:230-42.
136. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther. 2003;10:902-11.
137. Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis. 2009;68:1247-54.
138. Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science. 2007;317:580.
139. Williams DA. RAC reviews serious adverse event associated with AAV therapy trial. Mol Ther. 2007;15:2053-4.
140. Williams DA. NIH recombinant DNA Advisory Committee continues to ponder adverse event associated with AAV gene therapy trial. Mol Ther. 2008;16:427-8.
141. B rittberg M. Cell carriers as the next generation of cell therapy for cartilage repair: a review of the matrixinduced autologous chondrocyte implantation procedure. Am J Sports Med. 2010;38:1259-71.
142. von der Mark K, Gauss V, von der Mark H, Muller P. Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. Nature. 1977;267:531-2.
143. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12:301-15.
144. Tuan RS. Stemming cartilage degeneration: adult mesenchymal stem cells as a cell source for articular cartilage tissue engineering. Arthritis Rheum. 2006;54:3075-8.
145. Loken S, Jakobsen RB, Aroen A, Heir S, Shahdadfar A, Brinchmann JE, et al. Bone marrow mesenchymal stem cells in a hyaluronan scaffold for treatment of an osteochondral defect in a rabbit model. Knee Surg Sports Traumatol Arthrosc. 2008;16:896-903.